Referencias

1. Background Image: https://cdn.aarp.net/content/dam/aarp/health/conditions_treatments/2017/05/1140-pill-usa-opioids-aarp.imgcache.reva5ab0a8b1d6d8e63bb527fd5ccc8ea95.jpg
2. Alpert A., Powell D., & Liccardo R. (2017). Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids. Retrieved from https://www.nber.org/papers/w23031.
3. Bell, G. C., Donovan, K. A., & Mcleod, H. L. (2015). Clinical Implications of Opioid Pharmacogenomics in Patients with Cancer. Cancer Control, 22(4), 426-432. doi:10.1177/107327481502200408
4. Coplan P.M., Chilcoat H.D., Butler S.F., Sellers E.M., Kadakia A., Harikrishnan V., Haddox J.D. & Dart R.C. (2016). The Effect of an Abuse-Deterrent Opioid Formulation(OxyContin) on Opioid Abuse-Related Outcomes in the Postmarketing Setting. Clinical Pharmacology & Therapeutics, 100(3), 275-286. doi:10.1002/cpt.390
5. Gasior M., Bond M. & Malamut R. (2016). Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgraduate Medicine, 128(1), 85-96. https://doi.org/10.1080/00325481.2016.1120642
6. Green J.L., Bartelson B.B., Le Lait M.C., Roland C.L., Masters E.T., Mardekian J., Bailey J.E. & Dart R.C. (2017). Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug and Alcohol Dependence, 175, 140-145. https://doi.org/10.1016/j.drugalcdep.2017.01.039
7. Larochelle, M. R., Zhang, F., Ross-Degnan, D., & Wharam, J. F. (2015). Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA internal medicine, 175(6), 978-987.
8. Olkkola K.T., Kontinen V.K., Saari T.I. & Kalso E.A. (2013). Does the pharmacology of oxycodone justify its increasing use as an analgesic?. Trends in Pharmacological Sciences, 34(4), 206-214. https://doi.org/10.1016/j.tips.2013.02.001
9. Schaefer C.P., Tome M.E. & Davis T.P. (2017). The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. Fluids Barriers CNS, 14(32). DOI 10.1186/s12987-017-0080-3
10. Han, B., Compton, W. M., Jones, C. M., & Cai, R. (2015). Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013. Jama, 314(14), 1468. doi:10.1001/jama.2015.11859
11. Solimini, R., Pichini, S., Pacifici, R., Busardò, F. P., & Giorgetti, R. (2018). Pharmacotoxicology of Non-fentanyl Derived New Synthetic Opioids. Frontiers in Pharmacology, 9. doi:10.3389/fphar.2018.00654
12. https://drugabuse.com/library/oxycodone-abuse/
13. Hartney, E. (2018). The 10 Most Addictive Pain Killers. Retrieved from https://www.verywellmind.com/ten-most-addictive-pain-killers-22506
14. Ryan, H., Girion, L., & Glover, S. (2016). ‘You want a description of hell?’ OxyContin’s 12-hour problem. Los Angeles Times. Retrieved from http://www.latimes.com/projects/oxycontin-part1/
15. https://medlineplus.gov/spanish/druginfo/meds/a682132-es.html
16. Gomez-Vega C, Romero P, Callejo A, et al. (2007). Oxicodona en el dolor crónico no oncológico. Revista De La Sociedad Española Del Dolor, 14(2). ISSN 1134-8046 https://www.cochrane.org/es/CD003870/oxicodona-para-el-dolor-por-cancer
17. https://www.cochrane.org/es/CD010692/oxicodona-para-el-dolor-neuropatico-y-la-fibromialgia-en-adultos
18. Volkow, N. D., & McLellan, A. T. (2016). Opioid abuse in chronic pain—misconceptions and mitigation strategies. New England Journal of Medicine, 374(13), 1253-1263. 
19. Mayo Clinic- Oxycodone. Retrieved from https:/mayoclinic.org/drugs-supplements/oxycodone-oral-route/side-effects/drg-20074193 
20. Alcohol and Drug Foundation- Oxycodone. Retrieved from https:/adf.org.au/drug-facts/oxycodone/ 
21. Leow K, Cramond T, Smith MT (1995) Pharmacokinetics and pharmacodynamics of oxycodone when given intra-venously and rectally to adult patients with cancer pain. Anesth Analg 80:296-302 
22. Gallego, A. O., Barón, M. G., & Arranz, E. E. (2007). Oxycodone: a pharmacological and clinical review. Clinical and Translational Oncology, 9(5), 298-307.